The shot, called RTS,S or Mosquirix and developed by British drugmaker GlaxoSmithKline over 30 years in partnership with the PATH Malaria Vaccine Initiative, would be the first licensed human vaccine against a parasitic disease and could help prevent millions of cases of malaria in countries that use it. Recommendations for a drug licence made by the European Medicines Agency are normally endorsed by the European Commission within a couple of months.